Otezla® (apremilast) Co-Pay Program
Indications
Approved Uses Otezla® (apremilast) is a prescription medicine used for the treatment of:
  • Adult patients with plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Read more >
Approved Uses Otezla® (apremilast) is a prescription medicine used for the treatment of:
  • Adult patients with plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
  • Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
  • Adult patients with active psoriatic arthritis.
  • Adult patients with oral ulcers associated with Behçet’s Disease. Read less >

Get the support that works for you

No matter where you are in your treatment journey, we’re here to help every step of the way

Considering Otezla?
Email

Get Otezla information and resources for your upcoming appointment(s)

Already have an Otezla prescription?

Through Amgen® SupportPlus, you can enroll in the $0 Co-Pay* Program to help lower your out of pocket costs, and access dedicated Amgen Nurse Partner support and resources to help you start and stay on track with treatment.

Email
*Only for commercially insured patients. Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay-terms for full Terms and Conditions.
Amgen Nurse Partners are nurses by training, but they are not part of your treatment team or an extension of your doctor’s office. You will be referred to your doctor’s office for clinical advice

Whether you are considering Otezla or have been recently prescribed, you can sign up today for more information Thanks for signing up

*Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.
Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay-terms for full Terms and Conditions.
condition selection completed
Condition
Selection
patient information completed
Patient
Information
patient authorization completed
Patient
Authorization
Co-Pay card completed
Co-Pay
Card
Please fill out this form to enroll in Amgen® SupportPlus and more.
You’re almost done! If you have your prescription insurance information, please fill out the fields below.

All fields are required unless indicated as optional.

Choose your condition:
(Select all that apply)
Do you have a prescription for Otezla?
Select which best applies:
Personal information
Healthcare Representative:
Patient information:
Please enter valid address
Alternate address found. Please select one
Entered Address:
Suggested Address:
Contact information
Please enter valid email address
Please enter valid phone number
What type of insurance do you have?
(Select one)
The Otezla Co-Pay Card can help reduce out-of-pocket costs for eligible commercially insured patients.
Are you eligible for Medicare but receive prescription drug coverage from a former employer, union, or welfare plan?
By checking this box, I agree that I read, understand, and accept the Terms and Conditions of the Otezla Co-Pay Card
If you have Medicare or Medicaid coverage, our team of Amgen SupportPlus Representatives can assist you with any questions you may have about your plan. Our team is knowledgeable in Medicaid and can also review the Medicare Part D plan phases to help you understand what you can anticipate.
The Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Amgen medicines at no cost. Their contact information will be provided after your enrollment is complete.
Our team of Amgen SupportPlus Representatives may be able to help you figure out how to lower your out-of-pocket costs for Otezla. Their contact information will be provided after your enrollment is complete.
Amgen Nurse Partners are nurses by training, but they are not part of your treatment team or an extension of your doctor’s office. You will be referred to your doctor’s office for clinical advice.
Personal information
Please enter valid email address
Please enter valid phone number
Which best describes your experience?
Are you currently on treatment for your condition? (optional)
If yes, are you using a topical? (optional)
Co-Pay Card
Please fill out your prescription insurance information to complete your enrollment in the $0 Co-Pay Program.*

You are now signed up to learn the ins and outs of treatment with Otezla. Keep an eye on your email for more helpful information.

Woman on her laptop, in bed

Real patient experiences

Otezla has made a difference in lives of people just like you.
Amgen support plus logo

You are now signed up to learn the ins and outs of treatment with Otezla. Keep an eye on your email for more helpful information.

Two woman at a brunch gathering

What to expect on Otezla

Find out about managing side effects, seeing results, and more.

Your physical card will arrive through the mail in a few days, but you can start paying as little as $0* today.

You’re on your way. Here’s how to get started in 2 simple steps:

Share the following information with your specialty pharmacy
Share the following information with your specialty pharmacy
copay card
Once the pharmacist has your co-pay card information, it will be automatically applied each time you fill your Otezla prescription.
Your Otezla prescription will be delivered right to your
                        door
Your Otezla prescription will be delivered right to your door
Questions? Our Otezla team members are available
Monday – Friday, 8AM – 8PM ET, at 1-844-4OTEZLA (1-844-468-3952) to help you.
We’re with you along the way,
Your Otezla Team
*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay-terms for full Terms and Conditions.
Amgen support plus logo

Amgen SupportPlus provides assistance with everything from prior authorization to treatment questions. Keep an eye on your email for more helpful information.

SUMMARY OF TERMS AND CONDITIONS

It is important that every patient read and understand the full Amgen® SupportPlus Co-Pay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety. Please visit www.AmgenSupportPlus.com for full Terms and Conditions.

As further described below, in general:
  • The Amgen SupportPlus Co-Pay Card is open to patients with commercial insurance that covers an Amgen SupportPlus product, regardless of financial need. The program is not valid for patients whose prescription for an Amgen SupportPlus product is paid for in whole or in part by Medicare, Medicaid, or any other federal or state healthcare program. It is not valid for cash paying patients or where prohibited by law. (See ELIGIBILITY section in full Terms & Conditions.)
  • The Amgen SupportPlus Co-Pay Card may help lower your Amgen SupportPlus product out-of-pocket medication costs. Out-of-pocket costs include co-payment, co-insurance, and deductible out-of-pocket costs. The Amgen SupportPlus Co-Pay Card does not cover any other costs related to office visits or administration of the product. The Amgen SupportPlus Co-Pay Card provides support up to the Maximum Program Benefit or Patient Total Program Benefit. If a patient's commercial insurance plan imposes different or additional requirements on patients who receive Amgen SupportPlus Co-Pay Card benefits, Amgen has the right to modify or eliminate those benefits. Whether you are eligible to receive the Maximum Program Benefit or Patient Total Program Benefit is determined by the type of plan coverage you have. Please ask your Amgen SupportPlus Representative to help you understand eligibility for the Amgen SupportPlus Co-Pay Card, whether your particular insurance coverage is likely to result in your reaching the Maximum Program Benefit or your Patient Total Program Benefit amount by calling 1-833-44AMGEN (1-833-442-6436). (See PROGRAM BENEFITS section in full Terms & Conditions.)
  • Amgen SupportPlus patient may pay as little as $0 out-of-pocket for each prescription fill, dose or cycle of the Amgen SupportPlus product.
  • Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient until the Amgen payments have reached either the Maximum Program Benefit and/or the Patient Total Program Benefit. Patients are responsible for all amounts that exceed this limit. Please ask your Amgen SupportPlus Support Representative to help you understand eligibility for the Amgen SupportPlus Co-Pay Card by calling 1-833-44AMGEN (1-833- 442-6436) . (See PROGRAM DETAILS section in full Terms & Conditions.)
For Otezla® (apremilast) patients only:
  • Bridge to Commercial Coverage Offer: If the patient's health plan requires a prior authorization or if patient experiences a delay in obtaining approval for Otezla® (apremilast), the patient can receive Otezla free for up to twelve (12) prescription fills within twelve (12) months from the date of the first prescription filled under the Bridge to Commercial Coverage Offer while pursuing approval from patient's health plan. No purchase necessary. Once Otezla is approved by the patient's health plan, the patient is no longer eligible for the Bridge to Commercial Coverage Offer.
    • Ongoing eligibility after the first three (3) fills requires that the patient has a prior authorization or medical exception denied within ninety (90) days of first use of this offer. Once insurance approval is obtained, patient is no longer eligible for this offer.
    • This is a one-time offer and patients are ineligible to re-enroll.
  • See PROGRAM DETAILS section in full Terms & Conditions.
I. ELIGIBILITY

*Eligibility Criteria: Subject to program limitations and terms and conditions, the Amgen SupportPlus Co-Pay Card is open to patients who have been prescribed an Amgen SupportPlus product and who have commercial or private insurance that covers an Amgen SupportPlus product, including plans available through state and federal plans commonly referred to as “healthcare exchanges plans”. This program helps eligible patients cover out-of-pocket medication costs related to an Amgen SupportPlus product, up to program limits. The Amgen SupportPlus Co-Pay Card does not cover any other costs related to office visits or administration of an Amgen SupportPlus product. There is no income requirement to participate in this program.

This offer is not valid for patients whose prescription for an Amgen SupportPlus product is paid for in whole or in part by Medicare, Medicaid, or any other federal or state healthcare program. It is not valid for cash-paying patients or where prohibited by law. A patient is considered cash-paying where the patient has no insurance coverage for an Amgen SupportPlus product or where the patient has commercial or private insurance but Amgen in its sole discretion determines the patient is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Amgen SupportPlus product prescription. This offer is only valid in the United States, Puerto Rico, and the US territories.

II. PROGRAM BENEFITS

The Amgen SupportPlus Co-Pay Card also may modify the benefit amount, unilaterally determined by Amgen in its sole discretion, to satisfy the out-of-pocket cost sharing requirement for any patient whose plan or plan agent (including, but not limited to, a Pharmacy Benefit Manager (PBM)) requires enrollment in the Amgen SupportPlus Co-Pay Card as a condition of the plan or PBM waiving some or all of an otherwise applicable patient out-of-pocket cost sharing amount. These programs are often referred to as co-pay maximizer programs. If you believe your commercial insurance plan may have such limitations, please contact Amgen SupportPlus Support at 1-833-44AMGEN (1-833-442-6436). Health plans and Pharmacy Benefit Managers are prohibited from enrolling or assisting in the enrollment of patients in the Amgen SupportPlus Co-Pay Card. The patient, or his/her legal representative, must personally enroll in the Amgen SupportPlus Co-Pay Card in order to be eligible for program benefits.

If at any time a patient begins receiving coverage for medications under any federal, state, or government healthcare program (including but not limited to Medicare, Medicaid, TRICARE, Department of Defense, or Veteran Affairs programs), the patient will no longer be able to use this card and you must contact Amgen SupportPlus at 1-833-44AMGEN (1-833-442-6436) (Monday through Friday, from 8:00 am to 8:00 pm ET) to stop your participation in this program.

Patients may not seek reimbursement for the value received from the Amgen SupportPlus Co-Pay Card from any third-party payers, including a flexible spending account or healthcare savings account. Participating in this program means that you are ensuring you comply with any required disclosure regarding your participation in the Amgen SupportPlus Co-Pay Card of your insurance carrier or pharmacy benefit manager. Restrictions may apply. Offer subject to change or discontinuation without notice. This is not health insurance.

III. PROGRAM DETAILS
For all eligible patients the Amgen SupportPlus Co-Pay Card offers:
  • A program benefit that covers the patient's eligible out-of-pocket medication costs for the Amgen SupportPlus product (co-pay, deductible, or co-insurance) on behalf of the patient, up to a Maximum Program Benefit determined by the program per calendar year. The Amgen SupportPlus Co-Pay Card does not cover any other costs related to office visits or administration of an Amgen SupportPlus product
  • Amgen SupportPlus patients may pay as little as $0 out-of-pocket for each prescription fill, dose or cycle.
For Otezla® (apremilast) patients only:
  • Bridge to Commercial Coverage Offer: If the patient's health plan requires a prior authorization or if patient experiences a delay in obtaining approval for Otezla® (apremilast), the patient can receive Otezla free for up to twelve (12) prescription fills within twelve (12) months from the date of the first prescription filled under the Bridge to Commercial Coverage Offer while pursuing approval from patient's health plan. No purchase necessary. Once Otezla is approved by the patient's health plan, the patient is no longer eligible for the Bridge to Commercial Coverage Offer.
    • Ongoing eligibility after the first three (3) fills requires that the patient has a prior authorization or medical exception denied within ninety (90) days of first use of this offer. Once insurance approval is obtained, patient is no longer eligible for this offer.
    • This is a one-time offer and patients are ineligible to re-enroll.

Maximum Program Benefit, Patient Total Program Benefit, Benefits May Change, End or Vary Without Notice: The program provides up to a Maximum Program Benefit of assistance to reduce a patient's out-of-pocket medication costs that Amgen will provide per patient for each calendar year, which must be applied to the Amgen SupportPlus patient's out-of-pocket costs (co-pay, deductible, or co-insurance and annual out-of-pocket maximum). Patient Total Program Benefit amounts are unilaterally determined by Amgen in its sole discretion and will not exceed the Maximum Program Benefit. The Patient Total Program Benefit may be less than the Maximum Program Benefit, depending on the terms of a patient's plan, and may vary among individual patients covered by different plans, based on factors determined solely by Amgen, to ensure all programs funds are used for the benefit of the patient. Each patient is responsible for costs above the Patient Total Program Benefit amounts. Please ask your Amgen SupportPlus Support Representative to help you understand whether your particular insurance coverage is likely to result in your reaching the Maximum Program Benefit or your Patient Total Program Benefit amount by calling 1-833-44AMGEN (1-833-442-6436). Participating patients are solely responsible for updating Amgen with changes to their insurance including, but not limited to, initiation of insurance provided by the government, the addition of any coverage terms that do not apply Amgen SupportPlus Co-Pay Card benefits to reduce a patient's out-of-pocket costs, such as accumulator adjustment benefit design or a co-pay maximization program. Participating patients are responsible for providing Amgen with accurate information necessary to determine program eligibility. By accepting payments from Amgen made on behalf of participating patients, participating PBMs and Plans likewise are responsible for providing Amgen with accurate information regarding patient eligibility.

Patients may use the card every time they receive a dose or cycle of the Amgen SupportPlus product up to the Maximum Program Benefit or Patient Total Program Benefit. Benefits reset each calendar year. Re-enrollment in the program is required at regular intervals. Patients may continue in the program as long as patient re-enrolls as required by Amgen and continues to meet all of the program’s eligibility requirements during participation in the program. Patients can enroll/reenroll by calling 1-833-44AMGEN (1-833-442-6436).

IMPORTANT SAFETY INFORMATION

You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.

Otezla can cause allergic reactions, sometimes severe. Stop using Otezla and call your healthcare provider or seek emergency help right away if you develop any of the following symptoms of a serious allergic reaction: trouble breathing or swallowing, raised bumps (hives), rash or itching, swelling of the face, lips, tongue, throat or arms.

Otezla can cause severe diarrhea, nausea, and vomiting, especially within the first few weeks of treatment. Use in elderly patients and the use of certain medications with Otezla appears to increase the risk of complications from having severe diarrhea, nausea, or vomiting. Tell your doctor if any of these conditions occur.

Otezla is associated with an increase in depression. In clinical studies, some patients reported depression, or suicidal behavior while taking Otezla. Some patients stopped taking Otezla due to depression. Before starting Otezla, tell your doctor if you have had feelings of depression, or suicidal thoughts or behavior. Be sure to tell your doctor if any of these symptoms or other mood changes develop or worsen during treatment with Otezla.

Some patients taking Otezla lost body weight. Your doctor should monitor your weight regularly. If unexplained or significant weight loss occurs, your doctor will decide if you should continue taking Otezla. For children 6 years of age or older, their doctor should monitor their growth (height and weight). If they are not growing or gaining weight as expected, their doctor will decide if they should continue taking Otezla.

Some medicines may make Otezla less effective and should not be taken with Otezla. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines.

The most common side effects of Otezla include diarrhea, nausea, upper respiratory tract infection, tension headache, and headache. These are not all the possible side effects with Otezla. Ask your doctor about other potential side effects. Tell your doctor about any side effect that bothers you or does not go away.

Tell your doctor if you are pregnant, planning to become pregnant or planning to breastfeed.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-332-1088.

Please click here for the Full Prescribing Information for Otezla.

APPROVED USES

Otezla® (apremilast) is a prescription medicine used for the treatment of:

  • Adult patients with plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
  • Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
  • Adult patients with active psoriatic arthritis.
  • Adult patients with oral ulcers associated with Behçet’s Disease.

IMPORTANT SAFETY INFORMATION

You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.

Otezla can cause allergic reactions, sometimes severe. Stop using Otezla and call your healthcare provider or seek emergency help right away if you develop any of the following symptoms of a serious allergic reaction: trouble breathing or swallowing,